Tokai, a Cambridge, MA based Pharmaceutical company, just presented a promising set of Phase I data pointing to the early efficacy of its “triple whammy” pill for castration-resistant prostate cancer, TOK-001 or galeterone. In their phase 1 trial the PSA levels in about half of the 49 men in the dose-ranging study declined 30% or more in the trial, with 11 men registering a plunge of 50% or more in their PSA level. PSA levels, although not necessarily a marker for survival, are a commonly used biomarker for men with advanced prostate cancer.
TOK-001 is aimed at shutting down the three mechanisms involved in the development of castrate resistant prostate cancer (CRPC). The three mechanisms that TOK-001 goes after are: preventing the body from synthesizing new androgen by inhibiting the CYP17 enzyme, blocking the androgen receptor and then degrading the receptor.
You can read more about TOK-001 at:
Joel T Nowak, M.A., M.S.W.
Could you please advise….
Oncology prescribed Xofigo along with Zytiga when met progression on scans showed up.
We found an online warning from Bayer – maker of Xofigo -which stated not to combine these two drugs.
Oncologist immediately stopped Xofigo after one dose then Zytiga 60 days later.
No treatment for 60 days now and Pain level increasing.
What advise do you have?